Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Today’s low
6195.20Today’s High
6299.8052W low
4384.0052W High
6505.90Open Price
6195.20Prev. Close
5467.75Volume
635038.00Value
3992801425.00Market Cap Cr
104883.80
Price to Earnings
20.10
Price to Book Value
4.50
Dividend Yield
0.60
PE to Growth
0.50
Op Revenue TTM Cr
27212.50
Net Profit TTM Cr
5228.20
Cash From Operating Activity Cr
5887.50
Return on Equity %
19.35
EMA & SMA
Bullish Moving Averages
16
Bearish Moving Averages
0
DELIVERY AND VOLUME
02 May, 2024
Week
Month
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
PIVOT
First Resistance
6326.45
Second Resistance
6365.40
Third Resistance
6431.00
First Support
6221.90
Second Support
6156.30
Third Support
6117.35
Relative Strength Index
58.05
Money Flow Index
52.69
MACD
9.04
MACD Signal
-23.48
Average True Range
129.45
Average Directional Index
16.05
Rate of Change (21)
2.1
Rate of Change (125)
17.63
Commodity Channel Index
98
Williams %R
-8.4
BETA
1 Month
1.16
3 Month
0.37
1 Year
0.33
3 Year
0.01
PRICE CHANGE ANALYSIS
1 Week
Low
High
5928
6325
1 Month
Low
High
5880.8
6325
3 Months
Low
High
5880.8
6505.9
6 Months
Low
High
5247.1
6505.9
1 Year
Low
High
4384.05
6505.9
Indicator | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Qtr Revenue cr | 4330.60 | 5061.80 | 5670.90 | 4668.80 | 3949.00 | 4998.30 | 4034.00 | 3783.40 | 3542.60 | 3941.50 | 3619.70 | |
Operating Expenses Qtr | 3446.70 | 3209.60 | 3209.60 | 3488.80 | 3221.50 | 3077.50 | 3051.10 | 2989.00 | 2865.60 | 3075.10 | 2871.60 | |
Operating Profit Qtr | 656.30 | 1629.10 | 2227.70 | 1061.10 | 675.10 | 1802.80 | 579.50 | 669.90 | 614.00 | 748.30 | 561.90 | |
EBIDT Qtr Cr | 883.90 | 1852.20 | 2461.30 | 1175.90 | 726.50 | 1920.80 | 982.90 | 784.60 | 677.00 | 866.40 | 748.10 | |
Depreciation Qtr | 246.40 | 245.80 | 237.20 | 236.70 | 238.80 | 226.20 | 221.50 | 205.20 | 205.40 | 206.60 | 197.10 | |
Net Profit Qtr | 475.20 | 1192.60 | 1639.40 | 672.40 | 324.60 | 1116.30 | 499.50 | 419.70 | 341.10 | 449.00 | 413.40 | |
Basic EPS Qtr | 28.55 | 71.68 | 98.66 | 40.49 | 19.54 | 67.25 | 30.10 | 25.29 | 20.55 | 27.07 | 24.94 |
Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
---|---|---|---|---|---|---|
Total Revenue Annual | 17553.80 | 14887.20 | 14150.20 | 12593.60 | 10863.90 | |
Operating Expenses Annual Cr | 12747.70 | 11811.10 | 10212.30 | 8980.80 | 8325.80 | |
Operating Profit Annual | 4214.80 | 2594.10 | 3136.80 | 2869.60 | 2299.70 | |
Operating Profit Margin Annual % | 24.01 | 17.43 | 22.17 | 22.79 | 21.17 | |
Total Expenses Annual Cr | 13687.80 | 12663.40 | 11094.00 | 9817.80 | 9163.20 | |
EBIDT Annual Cr | 4806.10 | 3076.10 | 3937.90 | 3612.80 | 2538.10 | |
EBIDT Annual margin % | 27.38 | 20.66 | 27.83 | 28.69 | 23.36 | |
Depreciation | 923.20 | 814.30 | 835.00 | 789.20 | 780.60 | |
PAT Before ExtraOrdinary Items Annual Cr | 2612.80 | 1623.20 | 2186.40 | 2937.70 | 1277.30 | |
Net Profit Annual | 2612.80 | 1623.20 | 2186.40 | 2937.70 | 1277.30 | |
Basic EPS Annual | 157.37 | 97.85 | 131.84 | 177.23 | 76.98 |
Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
---|---|---|---|---|---|---|
Total ShareHolders Funds Annual | 20474.20 | 18336.20 | 16983.70 | 15191.90 | 12684.10 | |
Minority Interest Liability Annual Cr | - | - | - | - | - | |
Total Non Current Liabilities Annual Cr | 460.90 | 114.30 | 85.60 | 103.40 | 484.10 | |
Total Current Liabilities Annual Cr | 4439.70 | 6045.10 | 4560.30 | 4180.50 | 3079.30 | |
Total Capital Plus Liabilities Annual Cr | 25374.80 | 24495.60 | 21629.60 | 19475.80 | 16247.50 | |
Fixed Assets Annual | 8119.70 | 7350.80 | 6745.10 | 4845.70 | 5082.80 | |
Total Non Current Assets Annual | 11586.50 | 11012.00 | 10685.40 | 9369.10 | 7314.30 | |
Total Current Assets Annual | 13788.30 | 13483.60 | 10944.20 | 10106.70 | 8933.20 | |
Total Assets Annual | 25374.80 | 24495.60 | 21629.60 | 19475.80 | 16247.50 | |
Contingent Liabilities plus Commitments Annual Cr | 830.20 | 827.40 | 1062.80 | 1068.60 | 696.50 |
Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
---|---|---|---|---|---|---|
Cash from Operating Activity Annual | 5052.90 | 1338.70 | 3514.20 | 1839.20 | 2762.10 | |
Cash from Investing Activity Annual | -3447.60 | -2038.00 | -1458.00 | -1689.20 | -550.90 | |
Cash from Financing Annual Activity | -2696.90 | 505.50 | -794.30 | -224.10 | -2223.10 | |
Net Cash Flow Annual | -1091.60 | -193.80 | 1261.90 | -74.10 | -11.90 |
Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
---|---|---|---|---|---|---|
Book Value Per Share Annual | 1228.94 | 1101.93 | 1020.65 | 914.07 | 764.10 | |
ROE Annual % | 12.76 | 8.85 | 12.87 | 19.33 | 10.07 | |
ROCE Annual % | 18.54 | 12.25 | 18.17 | 18.46 | 13.34 | |
Total Debt to Total Equity Annual | 0.00 | 0.12 | 0.07 | 0.07 | 0.07 | |
EBDIT Annual Margin % | 28.33 | 21.35 | 29.49 | 30.48 | 23.88 |
Indicator | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Qtr Revenue cr | 7453.00 | 7217.60 | 6931.90 | 6453.70 | 6848.50 | 6372.60 | 6086.80 | 5596.80 | 5394.10 | 5992.40 | 5053.00 | |
Operating Expenses Qtr | 5213.70 | 4888.80 | 4694.70 | 4727.30 | 4837.90 | 4430.40 | 4291.70 | 4282.00 | 4117.90 | 4427.10 | 4210.60 | |
Operating Profit Qtr | 2023.10 | 2008.30 | 2062.10 | 1533.90 | 1938.50 | 1898.90 | 941.20 | 451.00 | 1215.70 | 1359.80 | 734.50 | |
EBIDT Qtr Cr | 2239.30 | 2323.30 | 2236.10 | 1672.40 | 1997.20 | 1939.70 | 1795.10 | 572.90 | 1271.50 | 1565.30 | 842.40 | |
Depreciation Qtr | 373.50 | 375.50 | 353.30 | 315.50 | 323.70 | 309.20 | 301.80 | 293.00 | 294.20 | 294.10 | 283.90 | |
Net Profit Qtr | 1380.90 | 1482.20 | 1405.00 | 960.10 | 1243.90 | 1114.20 | 1189.00 | 97.00 | 709.30 | 995.80 | 380.40 | |
Basic EPS Qtr | 82.94 | 89.09 | 84.55 | 57.79 | 74.91 | 67.13 | 71.64 | 5.84 | 42.75 | 60.03 | 22.95 |
Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
---|---|---|---|---|---|---|
Total Revenue Annual | 25725.20 | 22029.60 | 19338.90 | 18137.60 | 15785.70 | |
Operating Expenses Annual Cr | 18320.70 | 17777.50 | 15177.60 | 15046.60 | 12270.00 | |
Operating Profit Annual | 6349.00 | 3767.70 | 3869.90 | 2470.40 | 3178.20 | |
Operating Profit Margin Annual % | 24.68 | 17.10 | 20.01 | 13.62 | 20.13 | |
Total Expenses Annual Cr | 19713.70 | 19038.50 | 16503.40 | 16308.00 | 13493.70 | |
EBIDT Annual Cr | 7404.50 | 4252.10 | 4161.30 | 3091.00 | 3515.70 | |
EBIDT Annual margin % | 28.78 | 19.30 | 21.52 | 17.04 | 22.27 | |
Depreciation | 1250.20 | 1165.20 | 1228.80 | 1163.10 | 1134.80 | |
PAT Before ExtraOrdinary Items Annual Cr | 4470.30 | 2112.20 | 1903.60 | 1969.90 | 1906.20 | |
Net Profit Annual | 4507.30 | 2182.50 | 1951.60 | 2026.00 | 1950.00 | |
Basic EPS Annual | 270.90 | 131.21 | 117.34 | 121.99 | 117.33 |
Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
---|---|---|---|---|---|---|
Total ShareHolders Funds Annual | 23286.10 | 19212.40 | 17641.70 | 15598.80 | 14023.60 | |
Minority Interest Liability Annual Cr | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Non Current Liabilities Annual Cr | 426.90 | 768.70 | 871.30 | 412.40 | 2544.70 | |
Total Current Liabilities Annual Cr | 8572.10 | 9765.80 | 8103.80 | 7214.10 | 5897.30 | |
Total Capital Plus Liabilities Annual Cr | 32285.10 | 29746.90 | 26616.80 | 23225.30 | 22465.60 | |
Fixed Assets Annual | 9701.80 | 8867.60 | 9210.90 | 7894.10 | 9658.60 | |
Total Non Current Assets Annual | 11859.60 | 11964.60 | 12066.50 | 10626.20 | 11355.50 | |
Total Current Assets Annual | 20425.50 | 17782.30 | 14550.30 | 12599.10 | 11110.10 | |
Total Assets Annual | 32285.10 | 29746.90 | 26616.80 | 23225.30 | 22465.60 | |
Contingent Liabilities plus Commitments Annual Cr | 929.80 | 936.80 | 1077.40 | 1040.60 | 577.90 |
Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
---|---|---|---|---|---|---|
Cash from Operating Activity Annual | 5887.50 | 2810.80 | 3570.30 | 2984.10 | 2870.40 | |
Cash from Investing Activity Annual | -4137.30 | -2638.70 | -2266.00 | -492.30 | -772.70 | |
Cash from Financing Annual Activity | -2686.10 | -242.20 | -29.80 | -2515.90 | -2132.60 | |
Net Cash Flow Annual | -935.90 | -70.10 | 1274.50 | -24.10 | -34.90 |
Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
---|---|---|---|---|---|---|
Book Value Per Share Annual | 1397.72 | 1154.59 | 1060.20 | 938.56 | 844.79 | |
ROE Annual % | 19.35 | 11.35 | 11.06 | 12.98 | 13.90 | |
ROCE Annual % | 25.95 | 15.44 | 15.84 | 12.04 | 14.37 | |
Total Debt to Total Equity Annual | 0.05 | 0.16 | 0.15 | 0.11 | 0.24 | |
EBDIT Annual Margin % | 30.01 | 19.73 | 21.84 | 17.64 | 22.75 |
Name | Holding Percent | Holding Id | Pledged % | Locked % |
---|---|---|---|---|
HDFC TRUSTEE COMPANY LTD. A/C HDFC NIFTY 50 ETF | 1.62 | 75054981 | - | - |
NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2 | 2.3 | 75054986 | - | - |
GOVERNMENT OF SINGAPORE | 1.02 | 75054993 | - | - |
Name | Holding Percent | Holding Id | Pledged % | Locked % |
---|---|---|---|---|
KALLAM SATISH REDDY HUF | 3.31 | 75054964 | 0 | 0 |
GUNUPATI VENKATESWARA PRASAD HUF | 1.52 | 75054965 | 0 | 0 |
SAMRAJYAM REDDY KALLAM | 0.67 | 75054966 | 0 | 0 |
SATISH REDDY KALLAM | 0.54 | 75054967 | 0 | 0 |
APS Trust | 20.59 | 75054977 | 0 | 0 |
Name | Holding Percent | Holding Id |
---|---|---|
HDFC TRUSTEE COMPANY LTD. A/C HDFC NIFTY 50 ETF | 1.62 | 75054981 |
SBI-ETF NIFTY 50 | 1.42 | 75054982 |
FIRST SENTIER INVESTORS ICVC - STEWART INVESTORS ASIA PACIFIC LEADERS SUSTAINABILITY FUND | 2.32 | 75054992 |
GOVERNMENT OF SINGAPORE | 1.02 | 75054993 |
LIFE INSURANCE CORPORATION OF INDIA P & GS FUND | 5.05 | 75054984 |
J P Morgan Chase Bank NA | 15.35 | 75054989 |
NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2 | 2.3 | 75054986 |
Name | Holding Percent | Holding Id |
---|
Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
---|---|---|---|---|
Jul 11, 2023 | 40 | FINAL | - | Equity Share |
Jul 11, 2022 | 30 | FINAL | - | Equity Share |
Jul 09, 2021 | 25 | FINAL | - | Equity Share |
Jul 13, 2020 | 25 | FINAL | - | Equity Share |
Jul 15, 2019 | 20 | FINAL | - | Equity Share |
Jul 16, 2018 | 20 | FINAL | - | Equity Share |
Jul 17, 2017 | 20 | FINAL | - | Equity Share |
Jul 18, 2016 | 20 | FINAL | - | Equity Share |
Jul 10, 2015 | 20 | FINAL | - | Equity Share |
Jul 11, 2014 | 18 | FINAL | - | Equity Share |
Jul 12, 2013 | 15 | FINAL | - | Equity Share |
Jun 28, 2012 | 13.75 | FINAL | - | Equity Share |
Jun 30, 2011 | 11.25 | FINAL | - | Equity Share |
Jul 02, 2010 | 11.25 | FINAL | - | Equity Share |
Jul 03, 2009 | 6.25 | FINAL | - | Equity Share |
Jul 04, 2008 | 3.75 | FINAL | - | Equity Share |
Jul 06, 2007 | 3.75 | FINAL | - | Equity Share |
Jul 07, 2006 | 5 | FINAL | - | Equity Share |
Jul 07, 2005 | 5 | FINAL | - | Equity Share |
Jul 13, 2004 | 5 | FINAL | - | Equity Share |
Aug 08, 2003 | 5 | FINAL | - | Equity Share |
Aug 08, 2002 | - | FINAL | - | Equity Share |
Nov 08, 2001 | - | INTERIM | Nov 26, 2001 | Equity Share |
Jun 18, 2001 | - | FINAL | - | Equity Share |
Sep 07, 2000 | - | FINAL | - | Equity Share |
Ex-Date | Split Ratio | Record Date |
---|---|---|
Oct 10, 2001 | 10:5 | 2001-10-25 |
Ex-Date | Purpose | Notes |
---|---|---|
May 07, 2024 | Audited Results & Final Dividend | - |
Jan 30, 2024 | Quarterly Results | - |
Oct 27, 2023 | Quarterly Results | - |
Jul 26, 2023 | Quarterly Results | - |
May 10, 2023 | Audited Results & Final Dividend | - |
Jan 25, 2023 | Quarterly Results | - |
Oct 28, 2022 | Quarterly Results | - |
Jul 28, 2022 | Quarterly Results | - |
May 19, 2022 | Audited Results & Final Dividend | - |
Jan 28, 2022 | Quarterly Results | - |
Oct 29, 2021 | Quarterly Results | - |
Jul 27, 2021 | Quarterly Results | - |
May 14, 2021 | Audited Results & Final Dividend | - |
Jan 29, 2021 | Quarterly Results | - |
Oct 28, 2020 | Quarterly Results | - |
Jul 29, 2020 | Quarterly Results | - |
May 20, 2020 | Audited Results & Final Dividend | (Revised) |
May 13, 2020 | Audited Results & Final Dividend | - |
Mar 27, 2020 | Others | Inter alia, to consider and approve Raising of funds through issuance of Commercial Papers. |
Jan 27, 2020 | Quarterly Results | - |
Nov 01, 2019 | Quarterly Results | - |
Jul 29, 2019 | Quarterly Results | - |
May 17, 2019 | Audited Results & Final Dividend | - |
Feb 01, 2019 | Quarterly Results | - |
Oct 26, 2018 | Quarterly Results | - |
Jul 26, 2018 | Quarterly Results | - |
May 22, 2018 | Audited Results & Dividend | - |
Jan 25, 2018 | Quarterly Results | - |
Oct 31, 2017 | Quarterly Results | - |
Jul 27, 2017 | Quarterly Results | - |
May 12, 2017 | Audited Results & Dividend | - |
Feb 04, 2017 | Quarterly Results | - |
Oct 25, 2016 | Quarterly Results | - |
Jul 26, 2016 | Quarterly Results | - |
May 12, 2016 | Audited Results & Dividend | - |
Feb 17, 2016 | Buy Back of Shares | - |
Feb 09, 2016 | Quarterly Results | - |
Oct 29, 2015 | Quarterly Results | - |
Jul 30, 2015 | Quarterly Results | - |
May 12, 2015 | Audited Results & Final Dividend | - |
Jan 29, 2015 | Quarterly Results | - |
Oct 29, 2014 | Quarterly Results | - |
Jul 30, 2014 | Quarterly Results | - |
May 13, 2014 | Audited Results & Dividend | - |
Feb 11, 2014 | Quarterly Results | - |
Oct 31, 2013 | Quarterly Results | - |
Jul 30, 2013 | Quarterly Results | - |
May 14, 2013 | Audited Results & Dividend | - |
Feb 14, 2013 | Quarterly Results | - |
Oct 30, 2012 | Quarterly Results | - |
Jul 19, 2012 | Quarterly Results | - |
May 11, 2012 | Audited Results & Dividend | - |
Feb 03, 2012 | Quarterly Results | - |
Oct 25, 2011 | Quarterly Results | - |
Jul 20, 2011 | Quarterly Results | - |
May 13, 2011 | Audited Results & Dividend | - |
Jan 25, 2011 | Quarterly Results | - |
Oct 23, 2010 | Quarterly Results | - |
Jul 22, 2010 | Quarterly Results | - |
May 06, 2010 | Audited Results, Dividend & ESOP | To grant of 16,800 stock options, exercisable at par value of Rs. 5/- to the Independent Directors of the Co. under "Dr. Reddy's ESOS, 2002" & "Dr. Reddy's Employees ADR Stock Option Scheme, 2007". |
Mar 31, 2010 | Issuance of Bonus Debentures | For issuance of bonus debentures to Shareholders of the Co. from its General Reserves built from undistributed profits, The allotment of debentures will account for an amount not exceeding Rs. 520 Cr. |
Jan 20, 2010 | Quarterly Results | - |
Oct 23, 2009 | Quarterly Results | - |
Jul 21, 2009 | Quarterly Results | - |
May 18, 2009 | Audited Results, Dividend & Others | To grant of 9,000 stock options, exercisable at par value of Rs 5/- to the Independent Directors of the Co. under "Dr. Reddy's ESOS 2002" & "Dr. Reddy's Employees ADR Stock Option Scheme, 2007". |
Jan 20, 2009 | Quarterly Results | - |
Oct 23, 2008 | Quarterly Results & Amalgamation | To consider a Scheme of Amalgamation in terms of which Periecan Pharma Pvt. Ltd, a wholly owned subsidiary of the Company will be amalgamated with Dr. Reddy's Laboratories Ltd. |
Jul 21, 2008 | Quarterly Results | - |
May 20, 2008 | Audited Results & Dividend | - |
Jan 25, 2008 | Quarterly Results | - |
Oct 24, 2007 | Quarterly Results | - |
Jul 23, 2007 | Quarterly Results | - |
May 18, 2007 | Audited Results & Dividend | - |
Jan 22, 2007 | Quarterly Results | - |
Oct 27, 2006 | Quarterly Results | - |
Jul 27, 2006 | Quarterly Results | - |
May 31, 2006 | Accounts & Dividend | - |
Jan 24, 2006 | Quarterly Results | - |
Oct 29, 2005 | Quarterly Results | - |
Jul 26, 2005 | Quarterly Results | - |
May 06, 2005 | Accounts & Dividend | - |
Jan 31, 2005 | Quarterly Results | - |
Oct 26, 2004 | Quarterly Results | - |
Jul 27, 2004 | Quarterly Results | - |
Jan 30, 2004 | Quarterly Results | - |
Oct 28, 2003 | Quarterly Results | - |
Jul 31, 2003 | Quarterly Results | - |
May 30, 2003 | Accounts & Dividend | - |
Jan 28, 2003 | Quarterly Results | - |
Oct 24, 2002 | Quarterly Results | - |
Jul 31, 2002 | Quarterly Results | - |
Jun 04, 2002 | Accounts & Dividend | - |
Mar 04, 2002 | Interim Dividend | - |
Jan 29, 2002 | Quarterly Results | - |
Oct 31, 2001 | Quarterly, H.Y. Results & I. Dividend | - |
Jul 31, 2001 | Quarterly Results & Others | Stock Split & Employees Stock Option Plan |
May 30, 2001 | Accounts & Dividend | - |
Jan 30, 2001 | Quarterly Results | - |
Oct 30, 2000 | Quarterly Results | - |
Jul 28, 2000 | Quarterly Results | - |
Mar 23, 2000 | Interim Dividend and Issue of ADS | - |
Mar 06, 2000 | Merger | - |
Oct 20, 1999 | Quarterly Results | - |
Jul 29, 1999 | Quarterly Results | - |
Apr 19, 1999 | Accounts & Dividend | - |
Jan 30, 1999 | Quarterly Results | - |
Oct 21, 1998 | Quarterly Results | - |
Apr 27, 1998 | Accounts & Dividend | - |
May 17, 1997 | Accounts & Dividend. | - |
Ex-Date | Bonus Ratio | Record Date |
---|---|---|
Aug 28, 2006 | 1:1 | 2006-08-29 |
DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Change in Management
Intimation under Regulation 30DR.REDDY'S LABORATORIES LTD. - 500124 - Intimation Under Regulation 30
Intimation under Regulation 30Dr. Reddy's Laboratories recalls sapropterin dihydrochloride oral solution powder
Dr Reddy's Laboratories recalls oral solution powder over fears of reduced potency, associated health risksDr Reddy's Recalls Six Lots Of Drug In US Due To Subpotency
The issue was discovered during an accelerated stability test in addition to customer complaints.DR.REDDY'S LABORATORIES LTD. - 500124 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015Dr Reddy's rolls out condition management programme for irritable bowel syndrome
IBS is a functional gastrointestinal disorder characterised by abdominal pain, bloating and altered bowel habitsDR.REDDY'S LABORATORIES LTD. - 500124 - Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2024
Certiifcate under Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2024The latest market price of Dr. Reddy's Laboratories Ltd. on NSE was Rs. 6287.50 as of today.
The opening share price of Dr. Reddy's Laboratories Ltd. was Rs. 6195.20 as of today.
The 52-week high share price of Dr. Reddy's Laboratories Ltd. was Rs. 6505.90.
The 52 week low share price of Dr. Reddy's Laboratories Ltd. was Rs. 4384.00.
Dr. Reddy's Laboratories Ltd. has a market cap of Rs. 104883.80 crore as of today. Please refer to the Fundamentals section for further details.
The PE ratio of Dr. Reddy's Laboratories Ltd. is 0.50. Please refer to the Fundamentals section for further details.
The operating revenue for Dr. Reddy's Laboratories Ltd. in the last FY was Rs. 27212.50 crore. Please refer to the Financials section for further details.
The Net Profit for Dr. Reddy's Laboratories Ltd. in the last FY was Rs. 5228.20 crore. Please refer to the Financials section for further details.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
The latest dividend declared by Dr. Reddy's Laboratories Ltd. was on 2023-07-11 for Rs. 40 per share. According to today’s share price, the dividend yield of Dr. Reddy's Laboratories Ltd. stands at 0.60. Please refer to the Corporate Actions section for further details.
The latest bonus issue declared by Dr. Reddy's Laboratories Ltd. was as of 2006-08-28. The bonus ratio declared in this issue was 1:1. Please refer to the Corporate Actions section for further details.
The latest split issue declared by Dr. Reddy's Laboratories Ltd. was as of 2001-10-10. The split ratio declared in this issue was 10:5. Please refer to the Corporate Actions section for further details.
Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.
Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.
Please refer to the News section for the latest news about Dr. Reddy's Laboratories Ltd..